Barclays PLC increased its position in OmniAb, Inc. (NASDAQ:OABI - Free Report) by 321.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 143,215 shares of the company's stock after purchasing an additional 109,236 shares during the quarter. Barclays PLC owned 0.10% of OmniAb worth $606,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also added to or reduced their stakes in the company. Murchinson Ltd. acquired a new position in shares of OmniAb in the 3rd quarter valued at approximately $4,230,000. Dimensional Fund Advisors LP raised its holdings in OmniAb by 6.9% in the second quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company's stock valued at $11,296,000 after acquiring an additional 194,835 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in OmniAb by 6.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company's stock valued at $11,515,000 after acquiring an additional 163,038 shares during the last quarter. Squarepoint Ops LLC acquired a new position in OmniAb during the 2nd quarter worth $449,000. Finally, BBR Partners LLC increased its position in shares of OmniAb by 250.0% in the 3rd quarter. BBR Partners LLC now owns 70,000 shares of the company's stock worth $296,000 after purchasing an additional 50,000 shares during the last quarter. 72.08% of the stock is owned by institutional investors and hedge funds.
OmniAb Stock Performance
Shares of OmniAb stock traded up $0.03 during trading hours on Friday, reaching $3.21. The company's stock had a trading volume of 309,079 shares, compared to its average volume of 361,453. OmniAb, Inc. has a one year low of $3.16 and a one year high of $6.55. The company's 50 day simple moving average is $3.77 and its 200 day simple moving average is $4.07. The stock has a market cap of $453.32 million, a P/E ratio of -5.18 and a beta of -0.10.
Wall Street Analysts Forecast Growth
OABI has been the subject of a number of research reports. Benchmark reiterated a "buy" rating and issued a $8.00 price target on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th.
Get Our Latest Analysis on OABI
OmniAb Company Profile
(
Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Featured Articles
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
